As Big Molecule Watch continues to push past the bounds of biosimilars and into biologics, we are proud to announce the publication of two additional trackers concerning vaccines: the Vaccine Patent Litigation tracker and the Vaccine Patent PTAB tracker. These resources are dedicated to detailing the ever-changing landscape of patent infringement and patent challenges
Latest Post
More Posts
Now Available! Updated Goodwin’s Guide to Biosimilars Litigation and Regulation in the U.S., 2023-2024
Biosimilars Patent Challenges at the PTAB: Update and Lessons Learned
Patent Dance Disclosures and Beyond: Recent Biosimilars Litigation at the District Court
Legal Challenges to the Inflation Reduction Act: An Update on Pending Challenges and Reactions to Oral Argument in Dayton Area Chamber Of Commerce et al. v. Becerra et al.
So You Want To Make A Biosimilar: Top Considerations Before BLA Submission
Biosimilars Webinar Series
New Guidance & Ongoing Litigation: Summer 2023 Updates on the Inflation Reduction Act’s Medicare Drug Pricing Negotiation Program
Think You Don’t Need to Worry About Patents Before Commercializing Your Gene or Cell Therapy Product? Think Again! The Safe Harbor and Lessons Learned from REGENXBIO v. Sarepta.
Natasha Daughtrey to Speak at ACI’s 14th Annual Summit on Biosimilars & Innovator Biologics
Subscribe: Subscribe via RSS
Blogs
Firm/Org